Stoke Therapeutics Inc STOK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STOK is a good fit for your portfolio.
News
-
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
-
Stoke Therapeutics Announces Proposed Public Offering
-
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
-
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
-
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Trading Information
- Previous Close Price
- $10.29
- Day Range
- $10.35–16.40
- 52-Week Range
- $3.35–16.40
- Bid/Ask
- $14.55 / $14.79
- Market Cap
- $632.74 Mil
- Volume/Avg
- 56,609 / 982,504
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 71.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 110
Comparables
Valuation
Metric
|
STOK
|
CELC
|
ELVN
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.08 | 4.37 | 3.13 |
Price/Sales | 71.00 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
STOK
|
CELC
|
ELVN
|
---|---|---|---|
Quick Ratio | 6.54 | 10.54 | 9.78 |
Current Ratio | 6.99 | 11.15 | 10.28 |
Interest Coverage | — | −12.62 | — |
Quick Ratio
STOK
CELC
ELVN
Profitability
Metric
|
STOK
|
CELC
|
ELVN
|
---|---|---|---|
Return on Assets (Normalized) | −31.45% | −35.89% | −24.03% |
Return on Equity (Normalized) | −43.11% | −50.02% | −29.30% |
Return on Invested Capital (Normalized) | −47.87% | −39.18% | −35.22% |
Return on Assets
STOK
CELC
ELVN
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Blhbwyvhm | Lpkt | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hjpnnngxz | Pfzppm | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nrlktgsjg | Rjphsrr | $106.1 Bil | |
MRNA
| Moderna Inc | Stzmvwl | Vsnr | $42.3 Bil | |
ARGX
| argenx SE ADR | Ktfbzzpx | Dxggf | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Lmkkrlw | Khbwk | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mspstkjt | Ygfhbp | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fplxqjl | Xydqt | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jqfztbjxyp | Xhszw | $13.6 Bil | |
INCY
| Incyte Corp | Dswntjc | Bffmgx | $12.8 Bil |